WG
PALI icon

Winton Group’s Palisade Bio PALI Stock Holding History

Winton Group’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Buy
32,227
+20,727
+180% +$40.8K ﹤0.01% 1108
2026
Q1 		$20.1K Sell
11,500
-3,391
-23% -$6.17K ﹤0.01% 1078
2025
Q4 		$35K Buy
+14,891
New +$28.6K ﹤0.01% 909

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Winton Group's PALI Position: Q2 2026 in Review

Winton Group increased its Palisade Bio (PALI) stake by 180% in Q2 2026, buying an estimated $40.8K and bringing the position to 32,227 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Winton Group first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Winton Group held 32,227 shares of Palisade Bio worth $67.4K as of Q2 2026.
  • Winton Group bought 20,727 Palisade Bio shares in Q2 2026, an estimated $40.8K.
  • Palisade Bio made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1108 holding.
  • Winton Group first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.